KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer

被引：25

作者：

Jimeno, Antonio ^{[1
]}

Messersmith, Wells A. ^{[1
]}

Hirsch, Fred R. ^{[1
]}

Franklin, Wilbur A. ^{[1
]}

Eckhardt, S. Gail ^{[1
]}

机构：

[1] Univ Colorado, Ctr Canc, Denver, CO 80262 USA

来源：

CANCER JOURNAL | 2009年 / 15卷 / 02期

关键词：

KRAS; EGFR; biomarker; colorectal cancer; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; K-RAS MUTATIONS; POINT MUTATIONS; EGFR; INHIBITOR; IDENTIFICATION; HYBRIDIZATION; CHEMOTHERAPY; ONCOGENES;

D O I：

10.1097/PPO.0b013e31819e3202

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent retrospective evidence from several randomized studies has established that advanced colorectal cancer patients with tumors harboring a mutation in the KRAS gene do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitumumab. This represents a paradigm-changing event and will have substantial impact on current and future anticancer drug development. These results add to the economic and ethical considerations involved in the development of novel targeted therapies and should increase our scrutiny of mechanisms of resistance and predictive biomarkers while in earlier developmental stages. In this article. we will review the available clinical data and discuss the implications for future drug development in colorectal cancer.

引用

页码：110 / 113

页数：4

共 43 条

[31] mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt [J].

O'Reilly, KE ;

Rojo, F ;

She, QB ;

Solit, D ;

Mills, GB ;

Smith, D ;

Lane, H ;

Hofmann, F ;

Hicklin, DJ ;

Ludwig, DL ;

Baselga, J ;

Rosen, N .

CANCER RESEARCH, 2006, 66 (03) :1500-1508

[32] Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab:: A fluorescent in situ hybridization study [J].

Personeni, Nicola ;

Fieuws, Steffen ;

Piessevaux, Hubert ;

De Hertogh, Gert ;

De Schutter, Jef ;

Biesmans, Bart ;

De Roock, Wendy ;

Capoen, An ;

Debiec-Rychter, Maria ;

Van Laethem, Jean-Luc ;

Peeters, Marc ;

Humblet, Yves ;

Van Cutsem, Eric ;

Tejpar, Sabine .

CLINICAL CANCER RESEARCH, 2008, 14 (18) :5869-5876

[33] Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer [J].

Rao, S ;

Cunningham, D ;

de Gramont, A ;

Scheithauer, W ;

Smakal, M ;

Humblet, Y ;

Kourteva, G ;

Iveson, T ;

Andre, T ;

Dostalova, J ;

Illes, A ;

Belly, R ;

Perez-Ruixo, JJ ;

Park, YC ;

Palmer, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) :3950-3957

[34] Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer [J].

Rinehart, J ;

Adjei, AA ;

LoRusso, PM ;

Waterhouse, D ;

Hecht, JR ;

Natale, RB ;

Hamid, O ;

Varterasian, M ;

Asbury, P ;

Kaldjian, EP ;

Gulyas, S ;

Mitchell, DY ;

Herrera, R ;

Sebolt-Leopold, JS ;

Meyer, MB .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4456-4462

[35]

Ruiz MIG, 2007, CELL ONCOL, V29, P257

[36] IDENTIFICATION OF RAS ONCOGENE MUTATIONS IN THE STOOL OF PATIENTS WITH CURABLE COLORECTAL TUMORS [J].

SIDRANSKY, D ;

TOKINO, T ;

HAMILTON, SR ;

KINZLER, KW ;

LEVIN, B ;

FROST, P ;

VOGELSTEIN, B .

SCIENCE, 1992, 256 (5053) :102-105

[37] IDENTIFICATION OF P53 GENE-MUTATIONS IN BLADDER CANCERS AND URINE SAMPLES [J].

SIDRANSKY, D ;

VONESCHENBACH, A ;

TSAI, YC ;

JONES, P ;

SUMMERHAYES, I ;

MARSHALL, F ;

PAUL, M ;

GREEN, P ;

HAMILTON, SR ;

FROST, P ;

VOGELSTEIN, B .

SCIENCE, 1991, 252 (5006) :706-709

[38] The consensus coding sequences of human breast and colorectal cancers [J].

Sjoeblom, Tobias ;

Jones, Sian ;

Wood, Laura D. ;

Parsons, D. Williams ;

Lin, Jimmy ;

Barber, Thomas D. ;

Mandelker, Diana ;

Leary, Rebecca J. ;

Ptak, Janine ;

Silliman, Natalie ;

Szabo, Steve ;

Buckhaults, Phillip ;

Farrell, Christopher ;

Meeh, Paul ;

Markowitz, Sanford D. ;

Willis, Joseph ;

Dawson, Dawn ;

Willson, James K. V. ;

Gazdar, Adi F. ;

Hartigan, James ;

Wu, Leo ;

Liu, Changsheng ;

Parmigiani, Giovanni ;

Park, Ben Ho ;

Bachman, Kurtis E. ;

Papadopoulos, Nickolas ;

Vogelstein, Bert ;

Kinzler, Kenneth W. ;

Velculescu, Victor E. .

SCIENCE, 2006, 314 (5797) :268-274

[39] Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) [J].

Tejpar, S. ;

Peeters, M. ;

Humblet, Y. ;

Vermorken, J. B. ;

De Hertogh, G. ;

De Roock, W. ;

Nippgen, J. ;

von Heydebreck, A. ;

Stroh, C. ;

Van Cutsem, E. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[40] Mode of action and application of Scorpion primers to mutation detection [J].

Thelwell, N ;

Millington, S ;

Solinas, A ;

Booth, J ;

Brown, T .

NUCLEIC ACIDS RESEARCH, 2000, 28 (19) :3752-3761

← 1 2 3 4 5 →